{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:48:23Z","timestamp":1776984503197,"version":"3.51.4"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Despite current therapies for diabetic nephropathy, many patients continue to progress to end-stage renal disease requiring renal replacement therapy. While the precise mechanisms underlying diabetic nephropathy remain to be determined, it is well established that chronic activation of the renin angiotensin aldosterone system (RAAS) plays a substantial role in the pathogenesis of diabetic nephropathy. Angiotensin converting enzyme 2 (ACE2), the enzyme responsible for activating the reno-protective arm of the RAAS converts angiotensin (Ang) II into Ang 1-7 which exerts reno-protective effects. Chronic RAAS activation leads to kidney inflammation and fibrosis, and ultimately lead to end-stage kidney disease. Currently, angiotensin converting enzyme inhibitors and Ang II receptor blockers are approved for renal fibrosis and inflammation. Targeting the reno-protective arm of the RAAS should therefore, provide further treatment options for kidney fibrosis and inflammation. In this review, we examine how targeting the reno-protective arm of the RAAS can ameliorate kidney inflammation and fibrosis and rescue kidney function in diabetic nephropathy. We argue tissue ACE2 stimulation provides a unique and promising therapeutic approach for diabetic nephropathy.<\/jats:p>","DOI":"10.3389\/fphys.2021.813012","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T05:32:20Z","timestamp":1641879140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy"],"prefix":"10.3389","volume":"12","author":[{"given":"Haru","family":"Nomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjaya","family":"Kuruppu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niwanthi W.","family":"Rajapakse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"B1","year":"2020","journal-title":"43rd Anuual Report, Chapter 1: Incidence of Renal Replacement Therapy for End Stage Kidney Disease."},{"key":"B2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.mce.2008.09.020","article-title":"The sweeter side of ACE2: physiological evidence for a role in diabetes.","volume":"302","author":"Bindom","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.kint.2019.04.024","article-title":"Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.","volume":"96","author":"Cassis","year":"2019","journal-title":"Kidney Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"120058","DOI":"10.1016\/j.lfs.2021.120058","article-title":"Resistance exercise shifts the balance of renin-angiotensin system toward ACE2\/Ang 1-7 axis and reduces inflammation in the kidney of diabetic rats.","volume":"287","author":"de Alcantara Santos","year":"2021","journal-title":"Life Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"33678","DOI":"10.1038\/srep33678","article-title":"Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney.","volume":"6","author":"Domenig","year":"2016","journal-title":"Sci. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/01.res.87.5.e1","article-title":"A novel angiotensin-converting enzyme\u2013related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/01.HYP.0000215588.38536.30","article-title":"New mass spectrometric assay for angiotensin-converting enzyme 2 activity.","volume":"47","author":"Elased","year":"2006","journal-title":"Hypertension"},{"key":"B8","doi-asserted-by":"publisher","first-page":"F1606","DOI":"10.1152\/ajprenal.00063.2012","article-title":"Angiotensin-(1\u20137) attenuates diabetic nephropathy in Zucker diabetic fatty rats.","volume":"302","author":"Giani","year":"2012","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"F263","DOI":"10.1152\/ajprenal.00565.2017","article-title":"Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes.","volume":"315","author":"Gutta","year":"2018","journal-title":"Am. J. physiol. Renal physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/HYPERTENSIONAHA.113.02856","article-title":"Angiotensin-converting enzyme 2\u2013independent action of presumed angiotensin-converting enzyme 2 activators.","volume":"63","author":"Haber Philipp","year":"2014","journal-title":"Hypertension"},{"key":"B11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects.","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1161\/HYPERTENSIONAHA.107.108944","article-title":"Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents.","volume":"51","author":"Hern\u00e1ndez Prada Jos\u00e9","year":"2008","journal-title":"Hypertension"},{"key":"B14","year":"2019","journal-title":"IDF Diabetes Atlas"},{"key":"B15","doi-asserted-by":"publisher","first-page":"R169","DOI":"10.1152\/ajpregu.00387.2006","article-title":"Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. American journal of physiology-regulatory.","volume":"293","author":"Joyner","year":"2007","journal-title":"Integr. Comp. Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/hr.2009.191","article-title":"Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27.","volume":"33","author":"Kamilic","year":"2010","journal-title":"Hypertens. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1124\/jpet.108.146431","article-title":"Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog.","volume":"328","author":"Kluskens","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2337\/diacare.29.04.06.dc05-1873","article-title":"Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy.","volume":"29","author":"Konoshita","year":"2006","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.peptides.2018.10.015","article-title":"Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models.","volume":"112","author":"Kuipers","year":"2019","journal-title":"Peptides"},{"key":"B20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1177\/1087057111413919","article-title":"Prediction of off-target effects on angiotensin-converting enzyme 2.","volume":"16","author":"Kulemina","year":"2011","journal-title":"J. Biomol. Screen."},{"key":"B21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3109\/10715762.2011.560149","article-title":"Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1\u20137) mas receptor expression associated with its PPAR-\u03b3 agonist action.","volume":"45","author":"Lakshmanan","year":"2011","journal-title":"Free Radic. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/path.1670","article-title":"Renal ACE2 expression in human kidney disease.","volume":"204","author":"Lely","year":"2004","journal-title":"J. Pathol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"F353","DOI":"10.1152\/ajprenal.00144.2004","article-title":"The role of angiotensin converting enzyme 2 in the generation of angiotensin 1\u20137 by rat proximal tubules.","volume":"288","author":"Li","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000368486","article-title":"Urinary angiotensin converting enzyme 2 increases in patients with type 2 diabetic mellitus.","volume":"40","author":"Liang","year":"2015","journal-title":"Kidney Blood Pressure Res."},{"key":"B25","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","article-title":"Update of pathophysiology and management of diabetic kidney disease.","volume":"117","author":"Lin","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2119\/molmed.2010.00111","article-title":"Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition.","volume":"17","author":"Liu","year":"2011","journal-title":"Mol. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41401-019-0326-5","article-title":"Gut microbiota dysbiosis-induced activation of the intrarenal renin-angiotensin system is involved in kidney injuries in rat diabetic nephropathy.","volume":"41","author":"Lu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"B28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.lfs.2019.02.027","article-title":"Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy.","volume":"221","author":"Malek","year":"2019","journal-title":"Life Sci."},{"key":"B29","first-page":"751","article-title":"Diabetic kidney disease: diagnosis, treatment, and prevention.","volume":"99","author":"McGrath","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"B30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1046\/j.1523-1755.64.s86.12.x","article-title":"Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy.","volume":"64","author":"Mezzano","year":"2003","journal-title":"Kidney Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"F812","DOI":"10.1152\/ajprenal.00655.2013","article-title":"Angiotensin 1\u20137 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity.","volume":"306","author":"Mori","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ki.2012.83","article-title":"Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice.","volume":"82","author":"Nadarajah","year":"2012","journal-title":"Kidney Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2337\/db09-1218","article-title":"Human recombinant ACE2 reduces the progression of diabetic nephropathy.","volume":"59","author":"Oudit","year":"2010","journal-title":"Diabetes"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.3390\/ijms22115520","article-title":"Both specific endothelial and proximal tubular adam17 deletion protect against diabetic nephropathy.","volume":"22","author":"Palau","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s00134-020-06026-1","article-title":"Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis.","volume":"46","author":"Pan","year":"2020","journal-title":"Intensive Care Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","article-title":"Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: a positive feedback mechanism in the RAS.","volume":"66","author":"Patel","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/ki.2008.497","article-title":"Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease.","volume":"74","author":"Reich","year":"2008","journal-title":"Kidney Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"F629","DOI":"10.1152\/ajprenal.00516.2013","article-title":"Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice.","volume":"306","author":"Salem","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/hr.2009.231","article-title":"Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.","volume":"33","author":"Shiota","year":"2010","journal-title":"Hypertens. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/sj.ki.5002373","article-title":"ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice.","volume":"72","author":"Soler","year":"2007","journal-title":"Kidney Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"F398","DOI":"10.1152\/ajprenal.90488.2008","article-title":"Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan.","volume":"296","author":"Soler","year":"2009","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/HYPERTENSIONAHA.119.12873","article-title":"Urinary renin in patients and mice with diabetic kidney disease.","volume":"74","author":"Tang","year":"2019","journal-title":"Hypertension"},{"key":"B45","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1161\/01.HYP.0000060689.38912.CB","article-title":"Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.","volume":"41","author":"Tikellis","year":"2003","journal-title":"Hypertension"},{"key":"B46","doi-asserted-by":"publisher","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase.","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DMSO.S91245","article-title":"A local renal renin-angiotensin system activation via renal uptake of prorenin and angiotensinogen in diabetic rats.","volume":"9","author":"Tojo","year":"2016","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"B48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/HYPERTENSIONAHA.117.10406","article-title":"Angiotensin-(1\u20137) and Vascular Function.","volume":"71","author":"Touyz","year":"2018","journal-title":"Hypertension"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1470320316669880","DOI":"10.1177\/1470320316669880","article-title":"Quantification of systemic renin-angiotensin system peptides of hypertensive black and white African men established from the RAS-Fingerprint\u00ae.","volume":"17","author":"van Rooyen","year":"2016","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"B50","doi-asserted-by":"publisher","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.","volume":"277","author":"Vickers","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/bph.14687","article-title":"Blockade of myeloid differentiation 2 attenuates diabetic nephropathy by reducing activation of the renin-angiotensin system in mouse kidneys.","volume":"176","author":"Wang","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14728222.2019.1624721","article-title":"Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.","volume":"23","author":"Warren","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"B53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B54","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1161\/01.hyp.0000037979.53963.8f","article-title":"AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1\u20137) on the endothelium.","volume":"40","author":"Wiemer","year":"2002","journal-title":"Hypertension"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.kint.2016.09.032","article-title":"Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.","volume":"91","author":"Wysocki","year":"2017","journal-title":"Kidney Int."},{"key":"B56","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2.","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2337\/db06-0033","article-title":"ACE and ACE2 activity in diabetic mice.","volume":"55","author":"Wysocki","year":"2006","journal-title":"Diabetes"},{"key":"B58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-4939-6625-7_8","article-title":"Measurement of angiotensin converting enzyme 2 activity in biological fluid (ACE2).","volume":"1527","author":"Xiao","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e85958","DOI":"10.1371\/journal.pone.0085958","article-title":"Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells.","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"B60","doi-asserted-by":"publisher","first-page":"F1374","DOI":"10.1152\/ajprenal.00656.2011","article-title":"Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes.","volume":"302","author":"Yamaleyeva","year":"2012","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1096\/fj.201903149R","article-title":"Diabetes-induced upregulation of kallistatin levels exacerbates diabetic nephropathy via RAS activation.","volume":"34","author":"Yang","year":"2020","journal-title":"FASEB J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1161\/01.HYP.0000126192.27644.76","article-title":"Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice.","volume":"43","author":"Ye","year":"2004","journal-title":"Hypertension"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1681\/ASN.2006050423","article-title":"Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes.","volume":"17","author":"Ye","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/ki.2014.274","article-title":"Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade.","volume":"87","author":"Zhang","year":"2015","journal-title":"Kidney Int."},{"key":"B65","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1210\/en.2017-00752","article-title":"Nrf2 deficiency upregulates intrarenal angiotensin-converting enzyme-2 and angiotensin 1-7 receptor expression and attenuates hypertension and nephropathy in diabetic mice.","volume":"159","author":"Zhao","year":"2018","journal-title":"Endocrinology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1042\/CS20130223","article-title":"Valsartan slows the progression of diabetic nephropathy in db\/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.","volume":"126","author":"Zhou","year":"2014","journal-title":"Clin. Sci."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.813012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T05:32:24Z","timestamp":1641879144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.813012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":66,"alternative-id":["10.3389\/fphys.2021.813012"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2021.813012","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"article-number":"813012"}}